Many interesting studies in the field of prostate cancer (PC) were presented at ESMO 2024. In my opinion three studies deserve to be highlighted: one in the localized setting, one in the metastatic hormone-sensitive setting (mHSPC) and one in the metastatic castration resistant setting (mCRPC).
There were many new developments, including practice-changing clinical trials, presented at this year’s European Society of Medical Oncology (ESMO) Congress in Barcelona. From the vast number of abstracts available in the rapidly evolving field of thoracic oncology, we have selected one abstract that was of particular interest to us: Low-dose versus standard dose pembrolizumab for treatment of advanced-stage non-small cell lung cancer (NSCLC) – Results of the pre-planned interim analysis of the clinical trial NVALT-30
Neoadjuvant therapies have the potential to increase R0 resectability and thereby improving surgical outcomes. Two recent phase II trials, PANDAS/PRODIGE 44 (1) and NICHE-2 (2), investigated neoadjuvant treatment approaches for borderline resectable pancreatic cancer and locally advanced mismatch-repair deficient (dMMR) colon cancer, respectively, with notable implications for clinical practice.
Since 2009, trastuzumab combined with chemotherapy has been the standard of care for HER2-positive metastatic gastric (mGC) and gastroesophageal junction cancer (GEJ), based on findings from the phase 3 ToGA trial (1). However, despite this initial success, the following decade brought a series of negative phase 3 trials, leaving first-line treatment options for HER2-positive gastric and gastroesophageal cancers without significant advancements (2–5).
At ESMO 2024 in Barcelona, various studies regarding the management of non-muscle-invasive bladder cancer (NMIBC), muscle-invasive bladder cancer (MIBC) and locally advanced / metastatic (la/m) bladder cancer were presented. This article aims to give a short overview of one outstanding study of each group.
In this article we review 2 studies on CD19 CAR-T cells, which were presented at the annual meeting of the European Hematology Association (EHA) 2024 in Madrid, Spain. The first study investigates the efficacy and safety of CD19 CAR-T cell therapies in ≥75 years old patients. The second trial explores if CD19 CAR-T cells expressing interleukin-10 (IL-10) are more resilient to exhaustion and ultimately show a better response rate in DLBCL or B-ALL.
Cancer of unknown primary (CUP) represents a heterogeneous group of metastatic epithelial or undifferentiated neoplasms where the primary tumour remains undetectable despite a standardized diagnostic evaluation. It is a rare condition accounting for less than 5% of all cancers and poses unique diagnostic and therapeutic challenges (1).
This review summarizes two clinical trials focusing on different cancer treatment modalities: the STORM trial for oligorecurrent prostate cancer (PCa) with lymph node metastases in the pelvis after primary treatment, and the ORATOR trial comparing radiation therapy (RT) versus transoral robotic surgery (TORS) for early-stage oropharyngeal cancer
Eine australische Forschungsgruppe hat für Melanome spezifische Antikörper identifiziert. Mithilfe dieser Marker lassen sich schon früh Melanome aus einfachen Blutproben diagnostizieren.
Interview mit Vincent Gruntz über Visionen, Herausforderungen und die besondere Rolle der SAKK
Seit September 2024 leitet Vincent Gruntz die Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK). Nach einer Karriere in der Pharmaindustrie bringt er eine neue Perspektive in die Organisation, die seit 60 Jahren eine zentrale Rolle in der schweizerischen Krebsforschung spielt. Im Interview spricht er über seine Motivation, die grössten Herausforderungen in der klinischen Krebsforschung und seine Vision für die Zukunft der SAKK.